Actively Recruiting
Identification of Myocardial Ischemia with Magnetocardiography Using Single Photon Emission Computed Tomography as a Reference Standard
Led by Qilu Hospital of Shandong University · Updated on 2024-08-21
228
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
Sponsors
Q
Qilu Hospital of Shandong University
Lead Sponsor
C
Chongqing Emergency Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the ability of Magnetocardiography (MCG) to detect myocardial ischemia in patients suspected of having non-ST-elevation acute coronary syndrome (NSTE-ACS). The study uses Single Photon Emission Computed Tomography (SPECT) as the gold standard to determine the presence and severity of myocardial ischemia, aiming to compare MCG's effectiveness against this established imaging technique. Participants will undergo MCG and SPECT examinations to assess myocardial ischemia. SPECT serves as a reference standard to evaluate the accuracy of MCG in detecting ischemia. The study also examines MCG's performance in patients with coronary stenosis less than 50%, focusing on ischemia without obstructive coronary artery disease (INOCA). The observation period lasts from enrollment until discharge, up to 30 days. During the study, patients with symptoms of myocardial ischemia will be monitored and assessed through the two imaging methods. Researchers will measure the efficacy of MCG in identifying ischemia compared to SPECT results. Safety and eligibility are carefully evaluated, excluding certain conditions such as recent myocardial infarction or severe renal impairment. The study's total participation duration will be up to 30 days, including enrollment and discharge evaluations.
CONDITIONS
Brief Title
Diagnosis of Myocardial Ischemia With MCG Using SPECT as a Reference Standard
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Symptoms of myocardial ischemia such as angina pectoris
- Coronary artery angiography showing less than 70% stenosis at the most severe site or CT angiography showing non-severe stenosis
- Signed informed consent
You will not qualify if you...
- Absolute or relative contraindications to SPECT-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine allergy
- Non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, or moderate to severe valvular disease
- Hemodynamic instability (systolic blood pressure less than 90 mmHg or requiring vasoactive drugs), tachyarrhythmia, or atrioventricular block of first degree or higher not returned to normal
- Severe renal abnormality with eGFR less than 30 ml/min or dialysis
- Malignant tumors with predicted survival less than 1 year
- Pregnant or breastfeeding women
- Unable to undergo MCG due to device entry issues, metal implants interference, or deemed unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 days from enrollment until discharge
Participants undergo magnetocardiography (MCG) and single photon emission computed tomography (SPECT) to diagnose myocardial ischemia.
1 to 2 visits depending on imaging scheduling
Trial Site Locations
Total: 1 location
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012
Actively Recruiting
Research Team
J
Jiaojiao Pang, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here